Maxadilan-simile expression in Nyssomyia neivai, a sandfly vector in an endemic region of Brazil, and its immunogenicity in patients with American tegumentary leishmaniasis

• Published in: Memórias do Instituto Oswaldo Cruz Vol. 112; no. 2; pp. 116 - 122
• Main Authors: Aires, Juliana, Casanova, Claudio, Vernal, Sebastian, Nascimento, Margarida, Rodrigues, Sandra, Lerner, Ethan A, Roselino, Ana Maria
• Format: Journal Article
• Language: English
• Published: Brazil Instituto Oswaldo Cruz, Ministério da Saúde 01-02-2017; Fundação Oswaldo Cruz (FIOCRUZ)
• Subjects: Animals; Antibodies - blood; Antibodies - immunology; Brazil; Case-Control Studies; Endemic Diseases; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoblotting; Insect Proteins - analysis; Insect Proteins - immunology; Insect Vectors - chemistry; Insect Vectors - classification; leishmaniasis; Leishmaniasis, Cutaneous - blood; Leishmaniasis, Cutaneous - immunology; Male; Maxadilan protein; PARASITOLOGY; Polymerase Chain Reaction; Psychodidae; Psychodidae - chemistry; Psychodidae - classification; Rabbits; Sequence Analysis, DNA; TROPICAL MEDICINE; leishmaniasis; Psychodidae; Maxadilan protein
• ISSN: 0074-0276; 1678-8060; 1678-8060; 0074-0276
• DOI: 10.1590/0074-02760160351

Maxadilan (Max) is a salivary component in the sandfly Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral leishmaniasis. Max has a powerful vasodilatory effect and is a candidate vaccine that has been tested in experimental leishmaniasis. Nyssomyia neivai (Pinto 1926) is a vector of the pathogen responsible for American tegumentary leishmaniasis (ATL) in Brazil.
We searched for Max expression in Ny. neivai and for antibodies against Max in ATL patients.
cDNA and protein were extracted from the cephalic segment, including salivary glands, of Ny. neivai and analysed by polymerase chain reaction, DNA sequencing, and blotting assays. The results were compared with data obtained from Lu. longipalpis samples. We quantified antibodies against Max in serum samples from 41 patients with ATL (31 and 10 with the cutaneous and mucocutaneous forms, respectively) and 63 controls from the endemic northeastern region of São Paulo state, using enzyme-linked immunosorbent assay.
Recognition of a Max-simile peptide by specific antibodies confirmed expression of a Max sequence in Ny. neivai (GenBank EF601123.1). Compared to controls, patients with ATL presented higher levels of antibodies against Max (p = 0.004); 24.4% of the patients with ATL and 3.2% of the controls presented anti-Max levels above the cutoff index (p = 0.014). The anti-Max levels were not associated with the specific clinical form of ATL, leishmanin skin test response, absence or presence of amastigotes in histopathologic exam, results of indirect immunofluorescence testing for leishmaniasis, or duration of cutaneous form disease.
High serum anti-Max levels did not protect patients against ATL, but confirmed previous natural exposure to Ny. neivai bites in this ATL endemic region.